相关实验视频

Updated: Jun 27, 2026

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

11.9K

在耐火性多发性骨髓瘤中使用贝兰他马布 (Belantamab mafodotin,pomalidomide和dexamethasone):一个1/2阶段试验

Suzanne Trudel1, Arleigh McCurdy2, Martha L Louzada3

  • 1Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. suzanne.trudel@uhn.ca.

Nature medicine
|January 4, 2024
PubMed
概括

新型疗法对于复发性多发性骨髓瘤至关重要. 贝兰他马布 (Belantamab mafodotin) 加上波马利多米德和德克萨米,在三级耐火患者中显示了85.3%的整体反应率,提供了持久的反应和有希望的生存结果.

更多相关视频

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.2K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

107

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...